Drug intelligence / Profile preview

NNC0113-6891

Development stage: Phase 1
Lead developer: Novo Nordisk
Modality: Small Molecules
Administration: Intravenous

Overview

NNC0113-6891 is an investigational compound developed by Novo Nordisk. It appears to be part of a study investigating the pharmacokinetics of several compounds, including NNC0113-6891, when administered intravenously. Limited information is available about its specific mechanism of action or therapeutic purpose from the provided search results.

Beyond the preview

Go deeper on NNC0113-6891.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NNC0113-6891.

Explore the full profile